17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685

FOR IMMEDIATE RELEASE

Sun Pharma announces USFDA tentative approval for generic Aricept®

Mumbai, November 30, 2010: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Aricept®, donepezil hydrochloride tablets.

These generic donepezil hydrochloride tablets, equivalent to Eisai's Aricept® tablets, include two strengths: 5 mg and 10 mg. Annual sale in US for these strengths is approximately $ 2.5 billion.

Donepezil hydrochloride tablets are indicated in the treatment of dementia of the Alzheimer's type. Efficiency has been demonstrated in patients with mild, moderate and severe Alzheimer's disease.

Aricept® is a registered trademark of Eisai co. Ltd.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, ophthalmology and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota		Mira Desai	
Tel	+91 22 6645 5645, Xtn 605	Tel	+91 22 6645 5645, Xtn 606
Tel Direct	+91 22 66455605	Tel Direct	+91 22 66455606
Mobile	+91 98670 10529	Mobile	+91 98219 23797
E mail	uday.baldota@sunpharma.com	E mail	mira.desai@sunpharma.com